Plain-English translation of NCT05876182 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether vancomycin, an antibiotic taken by mouth, can help treat primary sclerosing cholangitis (PSC)—a serious liver disease where bile ducts become scarred and inflamed. About 70–80% of PSC patients also have inflammatory bowel disease. Early reports suggest this medication may improve symptoms and lab results, but researchers need to study it carefully in adults and older teenagers to confirm it's safe and effective.
Primary sclerosing cholangitis has no proven medical treatment that can stop it from getting worse, and patients face serious risks including liver failure and certain cancers. Recent research suggests that harmful bacteria in the gut may travel to the liver and cause damage—and this medication might help by changing the gut bacteria and reducing that damage.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to take either the medication or a placebo (a dummy pill) three times a day by mouth. Some participants will receive a lower dose of the medication, others a higher dose, and others placebo—neither you nor the researchers will initially know which you're receiving. You'll take tablets for several months while attending follow-up visits where blood tests and other assessments will monitor your liver function and any side effects.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
Italy